about
Advances in Use of Endoscopy, Radiology, and Biomarkers to Monitor Inflammatory Bowel Diseases.Role of nitric oxide in gastrointestinal inflammatory and ulcerative diseases: perspective for drugs development.Increased response and remission rates in short-duration Crohn's disease with subcutaneous certolizumab pegol: an analysis of PRECiSE 2 randomized maintenance trial data.Probiotic sonicates selectively induce mucosal immune cells apoptosis through ceramide generation via neutral sphingomyelinaseEvaluation of 5 versus 10 granulocyteaphaeresis sessions in steroid-dependent ulcerative colitis: a pilot, prospective, multicenter, randomized studySuperoxide dismutase ameliorates TNBS-induced colitis by reducing oxidative stress, adhesion molecule expression, and leukocyte recruitment into the inflamed intestine.Inflammatory bowel disease: pathogenesis and targets for therapeutic interventions.Randomized trial of tofacitinib in active ulcerative colitis: analysis of efficacy based on patient-reported outcomesMERTK as negative regulator of human T cell activationNanoencapsulated budesonide in self-stratified polyurethane-polyurea nanoparticles is highly effective in inducing human tolerogenic dendritic cells.Anemia increases gastric blood flow in noncirrhotic and cirrhotic patients.Radiation-induced intestinal inflammation.Crohn's disease: a review of current treatment with a focus on biologics.Loss of response and requirement of infliximab dose intensification in Crohn's disease: a review.Pancreatitis-associated protein does not predict disease relapse in inflammatory bowel disease patientsRole of 3.0-T MR colonography in the evaluation of inflammatory bowel disease.Colonic Crohn's disease: value of magnetic resonance colonography for detection and quantification of disease activity.Role of small-bowel endoscopy in the management of patients with inflammatory bowel disease: an international OMED-ECCO consensus.The second European evidence-based Consensus on the diagnosis and management of Crohn's disease: Definitions and diagnosis.Lessons to learn from Crohn's disease clinical trials: implications for ulcerative colitis.Systematic review: the use of ultrasonography, computed tomography and magnetic resonance imaging for the diagnosis, assessment of activity and abdominal complications of Crohn's disease.The London position statement of the World Congress of Gastroenterology on Biological Therapy for IBD with the European Crohn's and Colitis Organisation: safety.MRI of Crohn's disease: from imaging to pathology.Results of the 2nd part Scientific Workshop of the ECCO. II: Measures and markers of prediction to achieve, detect, and monitor intestinal healing in inflammatory bowel disease.Imaging indexes of activity and severity for Crohn's disease: current status and future trends.Infliximab salvage therapy after failure of ciclosporin in corticosteroid-refractory ulcerative colitis: a multicentre study.Imaging of the colon in inflammatory bowel disease: ready for prime time?Anti-inflammatory effects of low-dose radiotherapy. Indications, dose, and radiobiological mechanisms involved.Second European evidence-based consensus on the diagnosis and management of ulcerative colitis part 3: special situations.Development of the Paris definition of early Crohn's disease for disease-modification trials: results of an international expert opinion process.Cell therapies for IBD: what works?Clinical trials in luminal Crohn's disease: a historical perspective.A global consensus on the classification, diagnosis and multidisciplinary treatment of perianal fistulising Crohn's disease.Development of drugs to target interactions between leukocytes and endothelial cells and treatment algorithms for inflammatory bowel diseases.Magnetic resonance enterography in Crohn's disease: optimal use in clinical practice and clinical trials.Use of acid-suppressing drugs and the risk of bacterial gastroenteritis.Acute gastroenteritis is followed by an increased risk of inflammatory bowel disease.Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE): Determining Therapeutic Goals for Treat-to-Target.Biosimilar infliximab for inflammatory bowel disease: from concepts to clinical practice. Case study illustrated with CT-P13.A multicenter, randomized, double-blind study comparing famotidine with cimetidine in the treatment of active duodenal ulcer disease.
P50
Q30244411-4574567E-D7F2-4D87-B4CB-84E9CB2807C7Q31923098-5F689690-2D20-4859-A075-74ACE0F4E398Q33541428-1F2E1FE2-B0D1-4DBD-BD97-0CEEFB6D6BBDQ33847243-0D756968-4EED-4055-AEE2-717F3F61ABF3Q34098893-3502C10E-7555-414B-A5F9-A334210DB29FQ34326998-7A690C3D-476D-4275-9351-CFE87C94942CQ34419021-6911B187-B2C7-4211-8AC9-3415C4C2B792Q35068784-E46C9B22-D363-44B6-A948-96BC728F36A7Q35207099-AAB7522F-AD6C-4B58-A4E7-1584AAE1819BQ36091237-03C54D2B-CE1F-41E9-A950-8415DAD3C4F4Q36791486-BC8030D8-BBD5-47C8-AC49-CDB21F7D61BFQ36859132-0FFC4530-24D7-4408-8384-9B9379B5327BQ37011959-0593DFBF-F91B-47BF-8CA1-71CBE34B58E4Q37378998-8F85AB06-894A-4CF3-B9D8-FF0882527512Q37458548-0BCC50B8-A75D-4C71-8B60-3D27369AD526Q37485563-40D2BD2A-D9BF-4AFE-9B8E-13EDEEB438CCQ37523421-CFCCB432-6549-4504-A488-92B0B7068939Q37545775-90876938-A6BB-493C-9D57-EDE476E833C4Q37814539-B6B06602-6B06-475B-A2B9-C7F595D9D396Q37861858-70E82361-A59A-46D1-B59F-8A4A94CA7D92Q37880179-5D270340-3457-43E5-A9F1-A491A863C3F9Q37918330-86A449FD-2846-4F12-9097-C850D3994BB9Q37924164-3B57E3B3-32AF-460D-805D-60D29141A1E3Q37937183-43CB939B-402C-4975-B4CD-8D501D0EE181Q37954575-1B7F8220-C9D4-4224-B598-F0DEF423DEC4Q37964767-C40E2845-923A-40E9-951C-551F94F96290Q38015957-8350BB8B-82B2-426A-8C05-C1E4B25F1376Q38036141-8931AD4F-ED6F-40A4-AE19-B58317DF2616Q38049779-64B93C99-0E18-4D5F-B785-EB9E5C8B4C9DQ38065036-B1C62548-8ED6-4A31-A756-8D9B33561D84Q38155582-72455E70-43AA-46B2-9E4D-54F34989219BQ38212837-4E7C4A2A-9593-4A01-973F-F871A8D5C559Q38222052-6840D1B5-FD78-4A26-8943-778D671B4DABQ38249149-D24FCA90-4CC5-4FE1-AD7F-50D7709C2B13Q38293782-B7914B65-6670-43C4-BDE2-556EFCB1765EQ38459305-857483F5-8251-40C7-B359-A6D3336A25EBQ38468388-5C7CD1C4-11C7-42BD-9AC3-4CA5436563AAQ38572827-3E78C364-8E20-4C58-BF81-12FFC1128ED1Q38591241-57A69967-3C01-4DDD-AC25-6AB490E1A5A0Q39528896-70CA087A-78AC-4D5A-B909-98CD8FD3E418
P50
description
hulumtues
@sq
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Julian Panes
@ast
Julian Panes
@en
Julian Panes
@es
Julian Panes
@nl
Julian Panes
@sl
type
label
Julian Panes
@ast
Julian Panes
@en
Julian Panes
@es
Julian Panes
@nl
Julian Panes
@sl
prefLabel
Julian Panes
@ast
Julian Panes
@en
Julian Panes
@es
Julian Panes
@nl
Julian Panes
@sl
P1053
H-5991-2015
P106
P1153
55857704800
P21
P31
P3829
P496
0000-0002-4971-6902